Возраст домена | 19 лет |
Дата окончания | Истек срок регистрации |
PR | 4 |
ИКС | |
Страниц в Google | 26 |
Страниц в Яндексе | 8 |
Dmoz | Нет |
Яндекс Каталог | Нет |
Alexa Traffic Rank | 7480730 |
Alexa Country | Нет данных |
История изменения показателей | Авторизация |
Идет сбор информации... Обновить
Healthcare Venture Capital Investing in Early Stage Biotechnology Companies | The Column Group - TCG
n/a
Extraordinary starts here. The Column Group (TCG) is a science-driven healthcare venture capital firm that invests in early stage drug discovery companies.
UTF-8
195.04 КБ
2 500
68 589 симв.
58 349 симв.
Счетчик | Посетители за 24 часа | Просмотры | Просмотров на посетителя |
---|---|---|---|
![]() | Нет доступа | Нет доступа | n/a |
Ссылок в Alexa | 15 |
Данные linkpad ( 22 Апреля 2015 ) | |
Количество ссылок на сайт | 17 |
Количество доменов, которые ссылаются на сайт | 15 |
Количество найденных анкоров | 8 |
Исходящие (внешние) ссылки домена | 41 |
Количество доменов, на которые ссылается сайт | 22 |
Количество исходящих анкоров | 18 |
Внешние ссылки главной страницы ( 185 ) | |
a2biotherapeutics.com/ | VISIT SITE |
accenttx.com | VISIT SITE |
escientpharma.com/ | VISIT SITE |
proneurotech.com/ | VISIT SITE |
revolutionmedicines.com/ | VISIT SITE |
surrozen.com/ | VISIT SITE |
tenayatherapeutics.com/ | VISIT SITE |
investors.arcusbio.com/investors/stock-information/stock-quo... | RCUS Price |
arcusbio.com/ | VISIT SITE |
ribontx.com/ | VISIT SITE |
kallyope.com/ | VISIT SITE |
ir.gritstoneoncology.com/investors/stock-information | GRTS Price |
gritstoneoncology.com/ | VISIT SITE |
flxbio.com/#!press-release-8312015/cugj | FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 |
neuronatherapeutics.com/ | VISIT SITE |
oricpharma.com/ | VISIT SITE |
effector.com/ | VISIT SITE |
carmot-therapeutics.us/ | VISIT SITE |
ir.constellationpharma.com/stock-information/stock-quote-cha... | CNST Price |
constellationpharma.com | VISIT SITE |
ir.ngmbio.com/ | NGM Price |
ngmbio.com | VISIT SITE |
nurix-inc.com | VISIT SITE |
jnj.com/media-center/press-releases/johnson-johnson-complete... | VISIT SITE |
exonicstx.com/ | VISIT SITE |
news.bms.com/press-release/rd-news/bristol-myers-squibb-expa... | VISIT SITE |
immunedesign.com | VISIT SITE |
pelotontherapeutics.com | VISIT SITE |
gene.com/media/press-releases/14567/2014-07-01/genentech-ann... | VISIT SITE |
mskcc.org/blog/can-america-cure-cancer | President Obama's MOONSHOT challenge is advised by TCG's Science Partner (and Founder of Aragon, Seragon and ORIC) Charles Sawye... |
investors.vrtx.com/news-releases/news-release-details/vertex... | Exonics Therapeutics Acquired by Vertex, Expanding into New Disease Areas and Enhances Gene Editing Capabilities |
pelotontherapeutics.com/2019may21-merck-to-acquire-peloton | Peloton Therapeutics Acquired by Merck, Bolstering Oncology Pipeline |
ir.ngmbio.com/news-releases/news-release-details/ngm-bio-ann... | NGM Bio Announces Pricing of Initial Public Offering |
ir.gritstoneoncology.com/news-releases/news-release-details/... | Gritstone Oncology Announces First Patient Dosed in a Clinical Study Evaluating its Personalized Immunotherapy, GRANITE-001 |
ir.ngmbio.com/news-releases/news-release-details/ngm-bio-app... | NGM Bio Appoints Hsiao D. Lieu, M.D. as SVP, Chief Medical Officer and Alex DePaoli, M.D. to New Role of SVP, Chief Translationa... |
ir.immunedesign.com/news-releases/news-release-details/merck... | Immune Design acquired by Merck for approx. $300M |
kallyope.com/kallyope-inc-appoints-brett-lauring-chief-medic... | Kallyope Inc. Appoints Brett Lauring as Chief Medical Officer |
ribontx.com/ribon-press-release/ | Ribon Therapeutics Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer |
ngmbio.com/merck-exercises-option-for-ngm-bios-investigation... | Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes |
ir.constellationpharma.com/news-releases/news-release-detail... | Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishme... |
ir.gritstoneoncology.com/news-releases/news-release-details/... | Gritstone Oncology Announces FDA Fast Track Designation for GRANITE-001 for the Treatment of Colorectal Cancer |
carmot-therapeutics.us/2018/12/19/carmot-therapeutics-initia... | Carmot Therapeutics Initiates Phase 1 Trial to Treat Type 2 Diabetes |
ir.gritstoneoncology.com/news-releases/news-release-details/... | Gritstone Oncology Announces Publication in Nature Biotechnology of Neoantigen Identification Capabilities of its Artificial Int... |
ir.constellationpharma.com/news-releases/news-release-detail... | Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resista... |
ir.gritstoneoncology.com/news-releases/news-release-details/... | Gritstone Oncology Advances Solid Tumor Bispecific Antibody Program into Lead Optimization Phase; Appoints Vice President of Ant... |
kallyope.com/kallyope-inc-announces-21-million-expansion-ser... | Kallyope Inc. Announces $21 Million Expansion of Series B Financing |
ir.immunedesign.com/news-releases/news-release-details/immun... | Immune Design Reports Increased Overall Response Rate and Longer Progression Free Survival of Patients with Follicular Lymphoma ... |
ir.constellationpharma.com/news-releases/news-release-detail... | Constellation Pharmaceuticals Appoints Patrick Trojer, Ph.D., as Chief Scientific Officer |
oricpharma.com/oric-pharmaceuticals-appoints-matt-panuwat-as... | ORIC Pharmaceuticals Appoints Matt Panuwat as Chief Business Officer |
ngmbio.com/ngm-bio-announces-preliminary-results-from-phase-... | NGM Bio Announces Preliminary Results from Phase 1b Study of NGM313 in Obese, Insulin Resistant Subjects with Nonalcoholic Fatty... |
investors.arcusbio.com/investors/press-releases/press-releas... | Arcus Biosciences Presents Initial Data from the Phase 1 Dose-Escalation Study of AB122, its anti-PD-1 antibody, at the SITC 201... |
ngmbio.com/ngm-bio-announces-new-histology-data-from-phase-2... | NGM Bio Announces New Histology Data from Phase 2 Trial of NGM282 in Patients with NASH |
flxbio.com/sitc_2018_presentations/ | FLX Bio Highlights Phase 1 Data for FLX475 at SITC 2018 |
ngmbio.com/ngm-bio-announces-multiple-presentations-at-aasld... | NGM Bio Announces Multiple Presentations at AASLD’s The Liver Meeting®, Including New NASH Histology Data from the Phase 2 Trial... |
ir.constellationpharma.com/news-releases/news-release-detail... | Constellation Pharmaceuticals Receives FDA Fast Track Designation for CPI-0610 in Treatment of Myelofibrosis |
revolutionmedicines.com/media/revolution-medicines-acquires-... | REVOLUTION Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets |
ir.immunedesign.com/news-releases/news-release-details/immun... | Immune Design Announces Program Updates & Portfolio Prioritization for G100 and CMB305 |
ir.constellationpharma.com/news-releases/news-release-detail... | Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study of CPI-0610 in Myelofibrosis |
revolutionmedicines.com/media/revolution-medicines-announces... | REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumor... |
flxbio.com/flxbio-in-2018-fierce-15/ | FLX Bio Named By FierceBiotech as One of its “Fierce 15” Biotech Companies of 2018 |
ngmbio.com/ngm-bio-appoints-david-j-woodhouse-ph-d-as-chief-... | NGM Bio Appoints David J. Woodhouse, Ph.D. as Chief Executive Officer and Aetna Wun Trombley, Ph.D. as President and Chief Opera... |
ir.gritstoneoncology.com/news-releases/news-release-details/... | Gritstone Oncology Announces Pricing of Initial Public Offering |
investors.arcusbio.com/investors/press-releases/press-releas... | Arcus Biosciences Announces Initiation of Phase 1 Trial for AB154, its Anti-TIGIT Antibody |
ir.constellationpharma.com/node/6511 | Constellation Pharmaceuticals Announces Pricing of Initial Public Offering |
investors.arcusbio.com/investors/press-releases/press-releas... | Arcus Biosciences Announces FDA Clearance of INDs for AB928 and AB122 and Initiation of Phase 1/1b Program to Evaluate AB928 Com... |
accenttx.com/press-releases/accent-therapeutics-announces-pu... | Accent Therapeutics Announces Company Launch with $40 Million Series A Financing for Novel, Precision Cancer Treatments Targetin... |
businesswire.com/news/home/20180509005440/en/Escient-Pharmac... | Escient Pharmaceuticals Launches with $40 Million Series A Financing to Advance First-in-Class G Protein-Coupled Receptor (GPCR)... |
static1.squarespace.com/static/571efec459827e67f588008a/t/5a... | Nurix Appoints Nancy Pryer, Ph.D., Chief Development Officer |
prnewswire.com/news-releases/oric-has-appointed-jacob-chacko... | ORIC Has Appointed Jacob Chacko, MD as Chief Executive Officer |
revolutionmedicines.com/media/revolution-medicines-raises-56... | REVOLUTION Medicines Raises $56 Million Series B Financing at $1.50 per share |
effector.com/2018/04/16/effector-presents-data-on-the-discov... | eFFECTOR Presents Data on the Discovery and Structure of eFT226, a Novel Inhibitor of eIF4A, at the AACR 2018 Annual Meeting |
ngmbio.com/media/press-releases/041418/ | NGM Bio Announces Results From Phase 2 Study Of NGM282 In NASH Patients Demonstrating Clinically Significant Improvements In Liv... |
gritstoneoncology.com/news-1/2018/4/12/gritstone-oncology-to... | Gritstone Oncology to Present First Data Bridging Tumor Antigen Identification and Potent Immunotherapy Delivery in Primates at ... |
constellationpharma.com/constellation-pharmaceuticals-announ... | Constellation Pharmaceuticals Announces $100 Million Financing at $1.00 per share |
prnewswire.com/news-releases/surrozen-strengthens-leadership... | Surrozen Strengthens Leadership Team with Addition of Craig Parker as New CEO and Hans Clevers as Scientific Co-founder |
pelotontherapeutics.com/2018mar22-press-release#! | Peloton Therapeutics Appoints Helen S. Kim, M.B.A. and David Chang, M.D., Ph.D. to Board of Directors |
investors.arcusbio.com/investors/press-releases/press-releas... | Arcus Biosciences Announces Pricing of Initial Public Offering at $15 per share |
ir.immunedesign.com/news-releases/news-release-details/immun... | Immune Design Reports Data Update for Lead Immunotherapy Programs: Improvement in Survival for CMB305 Monotherapy in Sarcoma and... |
kallyope.com/kallyope-inc-announces-66m-series-b-financing-a... | Kallyope Announces $66M Series B Financing at $2.00 per share to Advance Programs Targeting the Gut-Brain Axis |
oricpharma.com/news/seriesc/ | ORIC Pharmaceuticals Announces $50 Million Series C Financing at $3.00 per share to Support Novel Therapies for Treatment-Resist... |
fiercepharma.com/marketing/fda-gives-j-j-s-erleada-a-quick-p... | Aragon's Drug ARN509 (Now Johnson&Johnson's Erleada) Gets Quick Push Over the Finish Line by the FDA, with First-Ever Non-Metast... |
onclive.com/web-exclusives/fda-approves-apalutamide-for-nonm... | Aragon's Drug Apalutamide Gets FDA Approval for Nonmetastatic Castration-Resistant Prostate Cancer |
youtube.com/watch?v=7ppUCugsWDQ | Biotech Showcase Video Interview with Jeff Jonker, President of NGM |
exonicstx.com/press-release/exonics-therapeutics-announces-p... | Exonics Therapeutics Announces Publication of Research Demonstrating Gene Repair Technology Corrected Cardiac Abnormalities Asso... |
gritstoneoncology.com/news-1/2018/1/23/gritstone-oncology-ap... | Gritstone Oncology Appoints Jean-Marc Bellemin as Chief Financial Officer |
carmot-therapeutics.us/2018/01/16/carmot-therapeutics-announ... | Carmot Therapeutics Announces Close of a $15M Series B Financing at $6.37 per share |
constellationpharma.com/constellation-pharmaceuticals-announ... | Constellation Pharmaceuticals Announces Initiation of Phase 1b/2 Study of CPI-1205 in Cancer Epigenetics |
constellationpharma.com/constellation-pharmaceuticals-announ... | Constellation Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 PROSTAR Combination Study of CPI-1205 in Advanced Form... |
exonicstx.com/press-release/exonics-therapeutics-raises-40-m... | Exonics Therapeutics Secures $40 Million in Series A Financing from The Column Group |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=1044103 | Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients |
effector.com/2017/10/04/effector-therapeutics-initiates-dosi... | eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and avelumab in Microsatellite Stable Colorectal C... |
gritstoneoncology.com/news-1/2017/9/6/gritstone-oncology-nam... | Gritstone Oncology Named as a "Fierce 15" Biotechnology Company of 2017 by FierceBiotech |
flxbio.com/copy-of-flx-bio-adds-drs-pardoll-an | FLX Bio Selects Immuno-Oncology Clinical Candidate, Phase 1 Clinical Study of CCR4 Antagonist FLX475 to Begin in Late 2017, Appo... |
businesswire.com/news/home/20170919005550/en | Arcus Biosciences Announces Option and License Agreement with Taiho Pharmaceutical Co. Ltd. |
revolutionmedicines.com/docs/RevMed_Ras_PR.pdf | REVOLUTION Medicines Reports Discovery that May Expand Range of Clinically Actionable Cancer Mutations |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=1039635 | Immune Design Presents New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Imm... |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=1038750 | Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress |
ngmbio.com/media/press-releases/042217/ | NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated with Nonalcoholic Steatohepatitis (NASH)... |
docs.wixstatic.com/ugd/2e5630_5a526ea5b21248f1812308432c2e4d... | FLX Flexing Against Suppression |
constellationpharma.com/constellation-pharmaceuticals-appoin... | Constellation Pharmaceuticals Appoints Adrian Senderowicz, M.D., as Senior Vice President and Chief Medical Officer |
pelotontherapeutics.com/press-release-ubiquitin-ligase-june-... | Peloton Therapeutics Launches Ubiquitin Ligase Research Platform |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=1028977 | Immune Design Updates Positive Data from Lead Cancer Immunotherapy Programs at ASCO Annual Meeting |
effector.com/2017/06/05/effector-therapeutics-presents-phase... | eFFECTOR Therapeutics Presents Phase I Data on EFT508, Its Lead Product Candidate, at ASCO 2017 |
flxbio.com/copy-of-flx-bio-aacr-ccr4-poster | FLX Bio Adds Distinguished Immuno-Oncology Experts, Dr. Drew Pardoll and Dr. Philip Greenberg, To Its Scientific Advisory Board |
constellationpharma.com/jigar-raythatha-rejoins-constellatio... | Jigar Raythatha Rejoins Constellation Pharmaceuticals as President and CEO |
pelotontherapeutics.com/vhl-press-release-may-2017/ | Peloton Therapeutics Initiates Patient Dosing in Phase 2 Study of PT2385 for von Hippel-Lindau Disease-associated Kidney Cancer |
gritstoneoncology.com/news-1/2017/5/24/gritstone-oncology-ap... | Gritstone Oncology Appoints Raphaël F. Rousseau, M.D., Ph.D., as Chief Medical Officer |
prnewswire.com/news-releases/surrozen-launches-into-regenera... | Surrozen Launches Into Regenerative Medicine With $33 Million in Series A Financing Led by The Column Group |
gladstone.org/about-us/news/tenaya-therapeutics-launches-goa... | Tenaya Therapeutics Launches with the Goal of Curing Heart Disease |
fiercebiotech.com/special-report/arcus-biosciences | Arcus Aims to Build an Immuno-Oncology Powerhouse to Offer a Rational Approach to Combination Therapy |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=982304 | Immune Design to Report Second Quarter 2016 Financial Results |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=965972 | Immune Design Presents New Preclinical Data on Advances of Two Separate Intratumoral Approaches at the American Association for ... |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=949566 | Immune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305 |
kallyope.com/kallyope-inc-launches-with-44m-series-a-financi... | Kallyope Inc. Launches with $44m Series A Financing to Harness the Potential of the Gut-Brain Axis |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=945964 | Immune Design Highlights G100 Preclinical Data Demonstrating Direct and Abscopal Tumor Regression, Long-Term Response and Synerg... |
oricpharma.com/news/oric-pharmaceuticals-announces-53-millio... | ORIC Pharmaceuticals Announces $53 Million Series B Financing to Support Discovery and Development of Novel Therapies for Treatm... |
marketwired.com/press-release/-2078296.htm | Neurona Therapeutics Launches With $23.5 Million in Series A Funding to Repair Damaged Neural Circuits |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=942208 | Immune Design Announces Start of Randomized Phase 2 Cancer Immunotherapy Combination Trial in Patients With Soft Tissue Sarcoma |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=940059 | Immune Design Presents Preclinical Data on G100 and ZVex(TM) in Combination With Check Point Inhibitors at the 2015 Society for ... |
igenica.com/media-article.php?id=13 | Igenica Biotherapeutics Enters Into a Strategic Oncology Research Agreement with MedImmune |
nurix-inc.com/pdfs/NurixCelgenePressRelease.pdf | Nurix and Celgene Announce Collaboration Targeting Protein Homeostasis for Next-Generation Therapies in Oncology, Inflammation a... |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=927304 | Immune Design Announces Phase 2 Cancer Immunotherapy Trial Collaboration |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=926762 | Immune Design and Merck to Collaborate on Combination Trials of Two Immune Design Immunotherapies With Merck's KEYTRUDA for Non-... |
gene.com/stories/the-value-of-the-right-partner?utm_source=T... | Seragon Highlighted in Genentech's "The Value of the Right Partner" |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=913063 | Immune Design Announces Positive Data from Three Phase 1 Studies at the 2015 American Society of Clinical Oncology (ASCO) Annual... |
businesswire.com/news/home/20150428005113/en/Constellation-P... | Constellation Pharmaceuticals Initiates Clinical Development of CPI-1205, a Novel Inhibitor of EZH2, in Patients with Lymphoma |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=906821 | Immune Design Prices Public Offering of Common Stock |
news.bms.com/press-release/rd-news/bristol-myers-squibb-comp... | Flexus Biosciences Announces Closing of its Acquisition by Bristol-Myers Squibb |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=904323 | Immune Design Announces Positive Topline Data From Three Phase 1 Clinical Trials of Immuno-Oncology Agents |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=904308 | Immune Design Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=903450 | Immune Design Announces Treatment of Patients With CMB305 Investigational Immuno-Oncology Agent |
ngmbio.com/media/past-press-releases/032415/ | NGM Biopharmaceuticals Announces Positive Phase 2 Clinical Data in Primary Biliary Cirrhosis Patients for NGM282, a First-in-Cla... |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=902799 | Immune Design Announces Upcoming Financial Results and Immuno-oncology Conference Presentation |
ngmbio.com/media/past-press-releases/030215/ | NGM Biopharmaceuticals Announces Expansion of Management Team |
news.bms.com/press-release/rd-news/bristol-myers-squibb-expa... | Flexus Biosciences Announces Aquisition Agreement with Bristol-Myers Squibb for IDO-1 Inhibitor Program |
ngmbio.com/media/past-press-releases/022315/ | NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=895850 | Immune Design Announces First Patients Dosed in Phase 1 Clinical Trial of G100 Investigational Immuno-Oncology Agent |
flexusbio.com/#!17dec2014-press-release-/c22yw | Flexus Biosciences, a Cancer Immunotherapy Company Focused on Agents for the Reversal of Tumor Immunosuppression (ARTIS), Announ... |
constellationpharma.com/wp-content/uploads/cddis2014396a.pdf | Constellation's bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neu... |
constellationpharma.com/wp-content/uploads/Moros_2014_Leukem... | Constellation observes synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-re... |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=882342 | Immune Design Provides Update For Clinical Trials |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=876534 | Immune Design and Sanofi Pasteur Design Enter Broad Collaboration for the Development of Herpes Simplex Virus Therapy |
nurix-inc.com/pdfs/NurixCEOAppointment_091814.pdf | Nurix, Inc. Names Arthur T. Sands, M.D., Ph.D., Chief Executive Officer |
biospace.com/News/seragon-pharmaceuticals-announces-closing-... | Seragon Pharmaceuticals Inc. Announces Closing of its Acquisition by Genentech |
youtu.be/-db7NnY8CRM | Genentech announces acquisition of Seragon’s SERDs program |
constellationpharma.com/2014/08/constellation-expands-clinic... | Constellation Expands Clinical Studies of CPI-0610 |
ir.immunedesign.com/releasedetail.cfm?ReleaseID=861724 | Immune Design Announces Pricing of Initial Public Offering |
gene.com/media/press-releases/14567/2014-07-01/genentech-ann... | Seragon Pharmaceuticals Announces Acquisition Agreement with Genentech |
immunedesign.com/wp-content/uploads/2014/06/ID-LV305-FPI-201... | Immune Design Announces Treatment of First Patient in Phase 1 Clinical Trial of LV305 Immuno-Oncology Agent |
immunedesign.com/wp-content/uploads/2014/05/Medi7510-GLAAS-F... | Immune Design’s GLAAS TM Discovery Platform Used in MEDI7510 Phase 1 Trial for Respiratory Syncytial Virus |
prnewswire.com/news-releases/seragon-pharmaceuticals-appoint... | Seragon Pharmaceuticals Appoints Debasish Roychowdhury, M.D. to its Clinical and Scientific Advisory Board and as Acting Chief M... |
constellationpharma.com/2014/04/constellation-pharmaceutical... | Constellation Pharmaceuticals will give a presentation on EZH2 and exhibit posters on EZH2 and BET at the AACR Annual Meeting, A... |
immunedesign.com/wp-content/uploads/2014/05/ID-AACR-2014-pos... | Immune Design's DCVex: A Novel Integration-Deficient Lentiviral Vector Technology that Incorporates Genetic and Post-translation... |
immunedesign.com/wp-content/uploads/2014/05/ID-AACR-2014-pos... | Immune Design's DCVex: A novel DC-targeted vector platform for cancer immunotherapy |
prnewswire.com/news-releases/seragon-pharmaceuticals-appoint... | Seragon Pharmaceuticals Appoints N. Anthony Coles, M.D. to Board of Directors |
igenica.com/media-article.php?id=9 | Igenica Biotherapeutics Enrolls First Patient in Phase 1 Study of IGN523 in Acute Myeloid Leukemia |
igenica.com/media-article.php?id=7 | Igenica Raises $14 Million in Additional Series C Funding to Advance Product Pipeline and Technology Platform |
thecolumngroup.com/news/ID-G100-FPI-2014_01_27.pdf | Immune Design Announces Treatment of First Patient in Phase 1 Clinical Trial of ID-G100, an Investigational Immuno-Oncology Agen... |
prnewswire.com/news-releases/immune-design-raises-up-to-49-m... | Immune Design Raises Up to $49 Million Series C Financing |
marketwired.com/press-release/seragon-pharmaceuticals-raises... | Seragon Pharmaceuticals Raises $30M in Series A Financing |
globenewswire.com/news-release/2013/10/01/577154/10050599/en... | Immune Design Appoints Jan Henrik ter Meulen, M.D., Chief Scientific Officer |
globenewswire.com/news-release/2013/09/05/571588/10047376/en... | Immune Design Appoints Richard T. Kenney, M.D., Chief Medical Officer |
marketwired.com/press-release/seragon-pharmaceuticals-launch... | Seragon Pharmaceuticals Launched, Focused on Selective Estrogen Receptor Degrader Platform (SERD) |
investor.jnj.com/releasedetail.cfm?releaseid=786092 | Johnson & Johnson completes acquisition of Aragon Pharmaceuticals, Inc. |
marketwired.com/press-release/aragon-pharmaceuticals-announc... | Aragon is acquired by Johnson & Johnson for up to $1 billion |
bioworld.com/content/ngms-series-c-garners-50m-ongoing-work-... | NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Ob... |
xconomy.com/san-francisco/2013/06/25/ngm-partners-seek-next-... | NGM, Partners Seek Next Diabetes Drug Targets Among GI Tract Hormones |
investor.jnj.com/releasedetail.cfm?releaseid=771753 | Aragon Pharmaceuticals Announces Acquisition by Johnson & Johnson |
cancerresearch.org/news-publications/news-at-cri/2013/june/i... | Immune Design Partners With Leading Cancer Organizations To Advance Novel Immunotherapy Research |
igenica.com/media-article.php?id=5 | Igenica Appoints Thi-Sau Migone, Ph.D., as Chief Scientific Officer |
marketwired.com/press-release/aragon-announces-first-patient... | Aragon Announces First Patient Dosed in Phase I Study of ARN-810 in Estrogen Receptor Positive Breast Cancer |
mercknewsroom.com/press-release/research-and-development-new... | Merck Announces Appointment of Roger M. Perlmutter, M.D., Ph.D., As President of Merck Research Laboratories; Peter S. Kim, Ph.D... |
marketwired.com/press-release/aragon-announces-key-strategic... | Aragon Hires Paul Cleveland as EVP of Corporate Strategy and Chief Financial Officer |
prnewswire.com/news-releases/aragon-pharmaceuticals-raises-5... | Aragon Pharmaceuticals Raises $50 Million in Series D Financing to Advance Promising Therapeutic Candidates for Hormone-Driven C... |
prnewswire.com/news-releases/aragon-pharmaceuticals-announce... | Aragon Pharmaceuticals Announces Clinical Results from Ongoing Phase II Trial Confirming Robust Anti-Tumor Activity and Tolerabi... |
fiercebiotech.com/special-reports/4-aragon-pharmaceuticals-2... | Aragon Pharmaceuticals Awarded 2012 Top 15 by FierceBiotech |
igenica.com/media-article.php?id=4 | Igenica Appoints Mary Haak-Frendscho, Ph.D., as Chief Executive Officer |
fiercebiotech.com/story/high-profile-investigator-tapped-lea... | Aragon’s Co-Founder, Charles L. Sawyers, M.D., Tapped to Lead $10M Prostate Cancer Program |
forbes.com/sites/davidshaywitz/2012/03/26/curing-diabetes-wi... | NGM mentioned in Forbes article "Curing Diabetes with Surgery: It Works - - Now Let’s Figure Out Why" |
mskcc.org/blog/charles-sawyers-elected-president-american-as... | Aragon’s Co-Founder, Charles L. Sawyers, M.D., Named President-Elect of the American Association for Cancer Research |
prnewswire.com/news-releases/aragon-pharmaceuticals-secures-... | Aragon Pharmaceuticals Secures $42 Million in Series C Financing to Advance Pipeline of Therapies Targeting Hormone-Driven Cance... |
prnewswire.com/news-releases/immune-design-corp-appoints-way... | Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer |
prnewswire.com/news-releases/immune-design-corp-appoints-guy... | Immune Design Corp. Appoints Guy F. Cipriani as Chief Business Officer |
linkedin.com/company/the-column-group | - |
statestreet.efrontcloud.com/columngroup/index.cfm | Investor Login |
Внутренние ссылки главной страницы ( 53 ) | |
index.php | <img> |
# | <img> |
dr-vishva-dixit-joins-the-column-group-as-science-partner.ht... | Dr. Vishva Dixit joins The Column Group as Science Partner |
helen-s-kim-joins-the-column-group-as-a-strategic-advisor.ht... | Ms. Helen S. Kim joins The Column Group as a Strategic Advisor |
dr-huda-zoghbi-and-dr-charles-zuker-join-the-column-group-as... | Dr. Huda Zoghbi and Dr. Charles Zuker join The Column Group as Science Partners |
dr-robert-tjian-joins-the-column-group-as-discovery-partner.... | Dr. Robert Tjian joins The Column Group as Discovery Partner |
the-column-group-raises-535-million-third-fund.html | The Column Group Raises $535 Million Third Fund |
dr-richard-scheller-joins-the-column-group-as-science-partne... | Dr. Richard Scheller joins The Column Group as Science Partner |
the-column-group-adds-to-its-team.html | The Column Group Adds to Its Team |
dr-charles-sawyers-joins-column-group-science-partner.html | Dr. Charles Sawyers joins The Column Group as Science Partner |
dr-larry-lasky-joins-column-group-partner.html | Dr. Larry Lasky joins The Column Group as a Partner |
dr-roger-perlmutter-joins-column-group-science-partner.html | Dr. Roger Perlmutter joins The Column Group as Science Partner |
images/Exonics shows CRISPR treats DMD in dogs.pdf | Exonics Shows CRISPR Treats DMD In Dogs |
images/Exonics Perlmutter BOD Press Release FINAL 01-30-18.p... | Exonics Therapeutics Appoints Roger M. Perlmutter, M.D., Ph.D., to Board of Directors |
images/BioCentury Inc. - New NASH readouts for NGM, Bristol ... | New NASH Readouts for NGM, Bristol |
images/REVOLUTION Medicines Raises $25 Million in Series A F... | REVOLUTION Medicines Raises $25 Million in Series A Financing from The Column Group |
images/Gritstone_Oncology_Series_A_10_20_15.pdf | Gritstone Oncology Announces $102 Million Series A Financing to Support Discovery and Development of Personalized Cancer Immunot... |
images/Constellation targets IPO after Genentech passes on t... | Constellation Targets IPO After Genentech Passes on Takeout |
neurona-therapeutics-closes-24-million-in-series-a-financing... | Neurona Therapeutics Closes $24 Million in Series A Financing |
oric-pharmaceuticals-raises-15-million-series-a-financing.ht... | ORIC Pharmaceuticals Raises $15 Million Series A Financing |
seragon-is-acquired-by-genentech-for-up-to-1-725-billion.htm... | Seragon is acquired by Genentech for up to $1.725 billion |
images/ID-G100-FPI-2014_01_27.pdf | Immune Design Announces Treatment of First Patient in Phase 1 Clinical Trial of ID-G305 Cancer Immunotherapy Agent |
images/Constellation_and_LLS_Start_CPI-0610_Clinical_Develop... | Constellation Pharmaceuticals Initiates Clinical Development of CPI-0610, a Novel BET Protein Bromodomain Inhibitor, in Patients... |
images/MedImmunePressRelease.061713.pdf | NGM Biopharmaceuticals and MedImmune, AstraZeneca’s Biologics Arm, Announce Agreement to Discover and Develop Therapies for Diab... |
images/NGM_Janssen_Collaboration.pdf | NGM Enters Agreement With Janssen to Discover and Develop Novel Therapeutics for Diabetes |
images/10_5_2012_Immune_Design.pdf | Immune Design Announces the Grant of Two Principle Technology Patents and a Recent Publication in the Proceedings of the Nationa... |
images/Constellation_9.20.12.pdf | Constellation Pharmaceuticals and The Leukemia & Lymphoma Society Partner to Develop Novel BET Inhibitor for the Treatment of He... |
images/Constellation.3.27.2012.pdf | Constellation Pharmaceuticals announced Mark A. Goldsmith, M.D., Ph.D., to Serve as Executive Chairman of the Board of Directors... |
images/Collaboration_01_17_12.pdf | Constellation Pharmaceuticals and Genentech Enter Broad Epigenetics Drug Discovery Collaboration |
images/Peloton_Series_A.pdf | Peloton Therapeutics Completes $18 Million Series A Financing |
images/IDC_042711.pdf | Immune Design Corporation Appoints Pharma and Biotech Executive Carlos V. Paya, MD, PhD as Chief Executive Officer |
images/Constellation_020111.pdf | Constellation Pharmaceuticals Expands Leadership Team with Drug Development Industry Veterans |
images/Constellation.1.5.2011.pdf | Constellation Pharmaceuticals Appoints Industry Veteran James E. Audia, Ph.D. as Chief Scientific Officer |
images/Immune_Design10.26.10.pdf | Immune Design Grants Adjuvant License to MedImmune |
images/NGM_10.4.10.pdf | NGM Biopharmaceuticals Names William J. Rieflin Chief Executive Officer and Director |
images/Aragon_8.9.10.pdf | Aragon Pharmaceuticals Doses First Patient in Phase 1/2 Clinical Trial of ARN-509 for Castration-Resistant Prostate Cancer |
images/Aragon_8.2.10.pdf | Aragon Pharmaceuticals Appoints Richard A. Heyman CEO |
images/Igenica_061010.pdf | Igenica, Inc. secures $24 million in Series B financing |
images/Constellation_060210.pdf | Constellation Pharmaceuticals Closes $22 Million in Series B Funding |
images/Aragon_Series_B.pdf | Aragon Pharmaceuticals Secures $22 Million in Series B Financing |
images/NGM_Series_B.pdf | NGM Biopharmaceuticals Raises $51 Million in Series B Financing and Appoints New Board Member |
images/HarlowLevineACSPR.pdf | Constellation's CSO and Scientific Advisor Receive Medal of Honor from American Cancer Society |
images/Aragon_SawyersLaskerPR091027.pdf | Aragon Pharmaceuticals' Founder, Dr. Charles Sawyers Awarded 2009 Lasker-DeBakey Clinical Medical Research Award |
images/NGM_ADL.pdf | NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, former Genentech CEO, to its Board of Directors |
images/Constellation_Cancer_Biologist.pdf | Constellation Pharmaceuticals Appoints Renowned Cancer Biologist Edward E. Harlow, Jr., Ph.D. as Company's CSO |
images/NGM_Press_Release_CBO.pdf | NGM Biopharmaceuticals Appoints Helen S. Kim as Chief Business Officer |
images/Constellation_apppoints_Goldsmith.pdf | Constellation Pharmaceuticals Appoints Mark A. Goldsmith, M.D., Ph.D. as CEO and Closes $17 Million in Funding |
images/Aragon_Announces.pdf | Aragon Pharmaceuticals Announces $8 Million Series A Financing |
images/Igenica_appoints.pdf | Igenica Appoints Dr. Mike Rothe as CEO After Closing Series A Financing |
images/FierceBiotech_Constellation.pdf | FierceBiotech Names Constellation Pharmaceuticals as One of the "Fierce 15" Biotech Companies of 2008 |
images/Immune_Raises_18_Million.pdf | Immune Design, Led By Star Scientists, Raises $18 Million To Build Vaccine Company |
images/Constellation_Closes.pdf | Constellation Pharmaceuticals Closes $32 Million in Series A Funding |
images/NGM_Press_Release_-021208.pdf | NGM Biopharmaceuticals Raises $25.5M |
Domain Name: THECOLUMNGROUP.NET
Registry Domain ID: 144970272_DOMAIN_NET-VRSN
Registrar WHOIS Server: whois.easydns.com
Registrar URL: http://www.easydns.com
Updated Date: 2015-09-15T21:47:23Z
Creation Date: 2005-03-04T12:33:43Z
Registrar Registration Expiration Date: 2016-03-04T12:33:43Z
Registrar: easyDNS Technologies, Inc.
Registrar IANA ID: 469
Registrar Abuse Contact Email: abuse@easydns.com
Registrar Abuse Contact Phone: +1.4165358672
Domain Status: clientTransferProhibited
Domain Status: clientUpdateProhibited
Registry Registrant ID:
Registrant Name: Harald Ekman
Registrant Organization: The Column Group, LLC
Registrant Street: 1700 Owens Street, Suite 595
Registrant City: San Francisco
Registrant State/Province: CA
Registrant Postal Code: 94158
Registrant Country: US
Registrant Phone: +1.4158652050
Registrant Phone Ext:
Registrant Fax: +1.4158652048
Registrant Fax Ext:
Registrant Email: hostmaster@thecolumngroup.net
Registry Admin ID:
Admin Name: Harald Ekman
Admin Organization: The Column Group, LLC
Admin Street: 1700 Owens Street, Suite 595
Admin City: San Francisco
Admin State/Province: CA
Admin Postal Code: 94158
Admin Country: US
Admin Phone: +1.4158652050
Admin Phone Ext:
Admin Fax: +1.4158652048
Admin Fax Ext:
Admin Email: hostmaster@thecolumngroup.net
Registry Tech ID:
Tech Name: Harald Ekman
Tech Organization: The Column Group, LLC
Tech Street: 1700 Owens Street, Suite 595
Tech City: San Francisco
Tech State/Province: CA
Tech Postal Code: 94158
Tech Country: US
Tech Phone: +1.4158652050
Tech Phone Ext:
Tech Fax: +1.4158652048
Tech Fax Ext:
Tech Email: hostmaster@thecolumngroup.net
Name Server: RUSH.EASYDNS.COM
Name Server: NIRVANA.EASYDNS.NET
Name Server: MOTORHEAD.EASYDNS.ORG
>>> Last update of WHOIS database: 2015-09-15T21:47:23Z <<<
This domain is being managed via EASYDNS
The DNS Hosting specialists since 1998
DNS Hosting / Dynamic DNS / Failover DNS / DNS Anycast
Unconditional Guarantee, No tricks, No gimmicks: http://easyDNS.com
System Status Updates: http://easyurl.net/easystatus
( Follow us on Twitter http://twitter.com/easydns )
You have 4 lookups left today
HTTP/1.1 200 OK
Server: Apache/2.4
Content-Type: text/html; charset=UTF-8
Date: Tue, 11 Jun 2019 15:31:23 GMT
Transfer-Encoding: chunked
Connection: Keep-Alive
Set-Cookie: X-Mapping-pjomflmm=7D53AD9E2EA6483585C6708D39D3BF60; path=/
Кнопка для анализа сайта в один клик, для установки перетащите ссылку на "Панель закладок"